Drug Profile
AS 101
Alternative Names: AS101; CB-06-02; IVAX-Q-101; IVX-Q-101; Ossirene; WAX-120337Latest Information Update: 04 Aug 2020
Price :
$50
*
At a glance
- Originator Bar-Ilan University
- Developer BioMAS; Cassiopea; Feramda
- Class Antineoplastics; Antipsoriatics; Antivirals; Infertility therapies; Nitrogen compounds; Organometallic compounds; Skin disorder therapies; Small molecules
- Mechanism of Action Immunomodulators; Integrin alpha4beta1 antagonists; Integrin alphaVbeta3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Genital warts
- Phase I/II Wet age-related macular degeneration
- Discontinued Acute myeloid leukaemia; Atopic dermatitis; Chemotherapy-induced damage; Female infertility; HIV infections; Male infertility; Myelodysplastic syndromes; Neurological disorders; Psoriasis; Thrombocytopenia
Most Recent Events
- 01 Jul 2020 Feramda terminates a phase I/II trial in Wet age-related macular degeneration in Israel (PO) due to the sponsor's decision (NCT03216538)
- 09 Mar 2020 Foamix has been acquired by Menlo Therapeutics
- 09 Jul 2019 Phase II for Genital warts is still ongoing in Israel (Cassiopea's pipeline - July 2019)